Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Ondine Biomedical shares Ottawa Hospital study on Steriwave nasal photodisinfection helping patients

Ondine Biomedical shares Ottawa Hospital study on Steriwave nasal photodisinfection helping patients

Ondine Biomedical V.P. for Clinical and Medical Affairs Jason Hickok joins Natalie Stoberman from the Proactive studios to share the results of its 2022 quality improvement study for Steriwave nasal photodisinfection.

Hickok says the study shows spine surgery patients treated with Ondine Biomedical’s Steriwave nasal photodisinfection on average had a 48 percent shorter length of stay in hospital compared with those not treated. The study also shows there was a 33 percent reduction in the rate of return to the emergency department, as well as a 51 percent reduction in the rate of readmissions.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK